Literature DB >> 1293057

The non-enzymatic inactivation of thirteen beta-lactam antibiotics in human faeces.

G Jansen1, F Weissing, H de Vries-Hospers, R Tonk, D van der Waaij.   

Abstract

In order to obtain a method that could predict the in vitro inactivation of an antibiotic in the digestive tract, the non-enzymatic inactivation of 13 beta-lactam antibiotics by human faeces was investigated. Benzylpenicillin, amoxicillin, amoxicillin/clavulanate, cloxacillin, piperacillin, temocillin, cefuroxime, cefamandole, cephradine, cefotaxime, ceftazidime, aztreonam and imipenem were mixed in six graded concentrations with faecal suspensions of 30 healthy volunteers. After incubation the remaining antimicrobial activity was measured by means of a serial dilution method. A relationship between the initial antibiotic concentration (Aia) and the remaining antimicrobial activity after incubation (Asd) was derived, namely: Asd = 1/2[(Aia-K-F)+square root ((Aia-K-F)2 + 4 K Aia)]. The parameters K and F represent the intrinsic dissociation constant and the amount of available bindingsites in the faeces, respectively. Asd values were predicted with a reasonable degree of accuracy for all thirteen antibiotics. Dissociation constants differed significantly between the penicillins and the cephalosporins but F- values did not differ between cephalosporins and penicillins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1293057     DOI: 10.1007/bf01710684

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Inactivation of aztreonam by faecal supernatants of healthy volunteers as determined by HPLC.

Authors:  G W Welling; G Groen
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

2.  Reversible binding of polymyxin B and neomycin to the solid part of faeces.

Authors:  M P Hazenberg; A M Pennock-Schröder; J P van de Merwe
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

3.  Inactivation of amoxycillin, clavulanate and the combination by faecal preparations from volunteers.

Authors:  G W Welling; G Groen
Journal:  J Antimicrob Chemother       Date:  1990-02       Impact factor: 5.790

4.  Binding to faeces and influence on human anaerobes of antimicrobial agents used for selective decontamination.

Authors:  M P Hazenberg; M Van de Boom; M Bakker; J P Van de Merwe
Journal:  Antonie Van Leeuwenhoek       Date:  1983-06       Impact factor: 2.271

5.  Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora.

Authors:  B Kemmerich; H Warns; H Lode; K Borner; P Koeppe; H Knothe
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  Biological inactivation by faeces of antimicrobial drugs applicable in selective decontamination of the digestive tract.

Authors:  E M Veringa; D van der Waaij
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

7.  Binding to and antibacterial effect of aztreonam, temocillin, gentamicin and tobramycin on human faeces.

Authors:  M P Hazenberg; A M Pennock-Schröder; J P van de Merwe
Journal:  J Hyg (Lond)       Date:  1985-10

8.  Norfloxacin binds to human fecal material.

Authors:  C Edlund; L Lindqvist; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

9.  Concentrations of nystatin in faeces after oral administration of various doses of nystatin.

Authors:  W Hofstra; H G de Vries-Hospers; D van der Waaij
Journal:  Infection       Date:  1979       Impact factor: 3.553

  9 in total
  2 in total

1.  The in vitro inactivation of thirteen beta-lactam antibiotics by other mechanisms than adsorption to faecal substance.

Authors:  H de Vries-Hospers; G Jansen; R Tonk; D Oenema; D van der Waaij
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

2.  Models of antimicrobial pressure on intestinal bacteria of the treated host populations.

Authors:  V V Volkova; C L Cazer; Y T Gröhn
Journal:  Epidemiol Infect       Date:  2017-05-02       Impact factor: 4.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.